News | June 01, 2021
Jubilant to invest US $92 mn to expand sterile injectable capacity
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
7.94 crore doses were made available to the states in May 2021
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The GMP certificate is valid for three years until April 2024.
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
Subscribe To Our Newsletter & Stay Updated
